ExpreS2ion Biotechnologies – Reverse share split and malaria commercialization
On 16 October 2024, ExpreS2ion Biotechnologies announced that the company had signed a term sheet with Serum Institute of India Private Limited (SIIPL), a leading global vaccine manufacturer, to commercialize malaria vaccines currently in Phase I and Phase II.
On 21 October 2024, a reverse share split of the company’s shares was resolved, whereby 40 existing shares would be consolidated into 1 share, which is effective today.
In connection with these announcements, we sat down with the company’s CEO Bent Frandsen to get more flavor on the news. Hear more about the potential partner on the malaria vaccines and the next steps, as well as the rationale behind carrying out a reverse share-split in the video.
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis 13:53, 30 October 2024.
